Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection

American Journal of Hematology

Volumn 76, Issue 4, 2004, Pages 368-372

  Uehara, Taeko ^a   Nakaseko, Chiaki ^a   Hara, Satoru ^a   Harima, Akane ^a   Ejiri, Megumi ^a   Yokota, Akira ^a   Saito, Yasushi ^a   Nishimura, Miki ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic active Epstein Barr virus infection (CAEBV); Cytotoxic T lymphocyte; Epstein Barr virus; Nonmyeloablative stem cell transplantation

Indexed keywords

ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; EPSTEIN BARR VIRUS; FEMALE; HEMATOLOGIC MALIGNANCY; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNITY; LYMPHOMA; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

ADOLESCENT; B-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; CHRONIC DISEASE; CYCLOSPORINE; DNA, VIRAL; DRUG RESISTANCE; EPSTEIN-BARR VIRUS INFECTIONS; ETOPOSIDE; FEMALE; HEPATITIS, VIRAL, HUMAN; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE ORGAN FAILURE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; TACROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 3342882523     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20121     Document Type: Article

References (22)

1. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001;98:280-286.
2. Ishihara S, Okada S, Wakiguchi H, Kurashige T, Morishima T, Kawa-Ha K. Chronic active Epstein-Barr virus infection in children in Japan. Acta Paediatr 1995;84:1271-1275.
3. Jones JF, Straus SE. Chronic Epstein-Barr virus infection. Annu Rev Med 1987;38:195-209.
4. Kuzushima K, Yamamoto M, Kimura H, et al. Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol 1996;103:192-198.
5. Kimura H, Tsuge I, Imai S, et al. Intact antigen presentation for Epstein-Barr virus (EBV)-specific CTL by a lymphoblastoid cell line established from a patient with severe chronic active EBV infection. Med Microbiol Immunol 1995;184:63-68.
6. Tsuge I, Morishima T, Kimura H, Kuzushima K, Matsuoka H. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection. J Med Virol 2001;64:141-148.
7. Ishida Y, Yokota Y, Tauchi H, et al. Ganciclovir for chronic active Epstein-Barr virus infection. Lancet 1993;341:560-561.
8. Sakai Y, Ohga S, Tonegawa Y, et al. Interferon-alpha therapy for chronic active Epstein-Barr virus infection: potential effect on the development of T-lymphoproliferative disease. J Pediatr Hematol Oncol 1998;20:342-346.
9. Kawa-Ha K, Franco E, Doi S, et al. Successful treatment of chronic active Epstein-Barr virus infection with recombinant interleukin-2. Lancet 1987;1:154.
10. Kimura H, Morita M, Tsuge I, et al. Vidarabine therapy for severe chronic active Epstein-Barr virus infection. J Pediatr Hematol Oncol 2001;23:294-299.
11. Teshima T, Miyaji R, Fukuda M, Ohshima K. Bone-marrow transplantation for Epslein-Barr-virus-associated natural killer cell-large granular lymphocyte leukaemia. Lancet 1996;347:1124.
12. Imashuku S, Naya M, Yamori M, et al. Bone marrow transplantation for Epstein-Barr virus-related clonal T cell proliferation associated with hemophagocytosis. Bone Marrow Transplant 1997;19:1059-1060.
13. Takami A, Nakao S, Yachie A et al. Successful treatment of Epstein-Barr virus-associated natural killer cell large granular lymphocytic leukaemia using allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1998;21:1279-1282.
14. Fujii N, Takenaka K, Hiraki A, et al. Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection. Bone Marrow Transplant 2000;26:805-808.
15. Okamura T, Hatsukawa Y, Arai H, Inoue M, Kawa K. Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. Lancet 2000;356:223-224.
16. Taketani T, Kikuchi A, Inatomi J, et al. Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002;29:531-533.
17. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-555.
18. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-1555.
19. Boyle TJ, Berend KR, DiMaio JM, Coles RE, Via DF, Lyerly HK. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery 1993;114:218-225.
20. Smith CA, Ng CY, Heslop HE, et al. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 1995;4:73-79.
21. Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002;100:4059-4066.
22. Hagihara M, Tsuchiya T, Ueda Y, et al. Successful in vitro generation of Epstein-Barr virus-specific cytotoxic T lymphocytes from severe chronic active EBV patients. Med Microbiol Immunol 2001;189:137-145.